ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Metastatic Bladder Giant Cell Urothelial Carcinoma
Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Metastatic Bladder Giant Cell Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Fred Hutchinson Cancer Center | Phase 2/3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2/3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Vasgene Therapeutics, Inc | Phase 2/3 | B |
Relatlimab National Cancer Institute (NCI) | Phase 2/3 | B |
Recombinant Ephb4-Hsa Fusion Protein Vasgene Therapeutics, Inc | Phase 2/3 | CCC |
View all 15 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →